Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte Dreno

Showing results (181-190 of 213) with videos related to

Pageof 22
Sort By:
JAMA Dermatology|May 2, 2019
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and SurvivalAnaïs Vallet, Bastien Oriano, Laurent Mortier, et al.
Journal of the American Academy of Dermatology|November 29, 2005
Defining early mycosis fungoidesNicola Pimpinelli, Elise A Olsen, Marco Santucci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaAntoni Ribas, Richard Kefford, Margaret A Marshall, et al.
Blood|August 16, 2011
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphomaWerner Kempf, Katrin Pfaltz, Maarten H Vermeer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 7, 2024
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumorsElise Jirovec, Dafne C A Quixabeira, James H A Clubb, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in FranceMarguerite Kandel, Aurélie Bardet, Stéphane Dalle, et al.
Dermatology Practical & Conceptual|May 22, 2025
Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi ConsensusGabriella Brancaccio, Giulia Briatico, Zoe Apalla, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Pageof 22

Showing results (181-190 of 213) with videos related to

Sort By:
Pageof 22
JAMA Dermatology|May 2, 2019
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and SurvivalAnaïs Vallet, Bastien Oriano, Laurent Mortier, et al.
Journal of the American Academy of Dermatology|November 29, 2005
Defining early mycosis fungoidesNicola Pimpinelli, Elise A Olsen, Marco Santucci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaAntoni Ribas, Richard Kefford, Margaret A Marshall, et al.
Blood|August 16, 2011
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphomaWerner Kempf, Katrin Pfaltz, Maarten H Vermeer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 7, 2024
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumorsElise Jirovec, Dafne C A Quixabeira, James H A Clubb, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in FranceMarguerite Kandel, Aurélie Bardet, Stéphane Dalle, et al.
Dermatology Practical & Conceptual|May 22, 2025
Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi ConsensusGabriella Brancaccio, Giulia Briatico, Zoe Apalla, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Pageof 22